In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...

Novo Nordisk's high dose Wegovy (semaglutide) has shown improved weight loss while remaining safe and tolerable. In the Phase ...

Enobosarm demonstrated a statistically significant benefit in preserving lean mass in patients with overweight or obesity ...

Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...

Yeah, ouch. A new study found that men who took semaglutide (Wegovy) for weight loss were more likely to develop erectile dysfunction and low testosterone than those who didn’t. These drugs may ...

Novo Nordisk (NVO) stock slipped after ate-stage trial data for a higher-dose version of its popular obesity therapy, ...

Weight-loss drugs such as Ozempic and Wegovy could boost health in numerous other ways ... noting the data would be “heavily ...

A new study highlighted Monday the potential benefits of popular diabetes drugs on a wide range of health issues including ...

Weight loss drugs Ozempic and Wegovy have been added to the list of ... build on 10 previously announced and negotiated drugs. The results of those negotiations were announced in August.

Novo Nordisk's high dose Wegovy (semaglutide) has shown improved weight loss while remaining safe ... vice-president Martin Holst Lange said: “Results from STEP UP further strengthen the ...